Long-term Tolerability and Efficacy of Lamotrigine in Infants 1 to 24 Months Old

Abstract

This open-label study was designed to evaluate the long-term tolerability and efficacy of lamotrigine in 1- to 24-month-old infants with partial seizures. The study enrolled both lamotrigine-naïve patients and patients who had been previously exposed to lamotrigine in a randomized, double-blind, placebo-controlled study. Patients (n = 204) received lamotrigine according to a dosing schedule that depended on prior experience with lamotrigine and concurrent antiepileptic drug therapy for up to 48 weeks or their second birthday, whichever occurred last. Total duration of lamotrigine exposure (which included exposure during the placebo-controlled study in lamotrigine-experienced patients) was ≥24 weeks in 92% of patients, ≥48 weeks in 70% of patients, and ≥72 weeks in 20% of patients. A total of 20 (10%) patients (8 lamotrigine-naïve patients and 12 lamotrigine-experienced patients) transitioned to lamotrigine monotherapy. The most common adverse events were pyrexia (45% of patients), upper-respiratory tract infection (28%), and ear infection (22%). The only adverse event considered reasonably attributable to study medication in >2% of patients was irritability (n = 10; 5% of patients). No cases of serious rash were reported. The median percent reduction from baseline in partial seizure frequency in the sample as a whole was 74%. Seizure frequency was reduced by ≥50% from pre-lamotrigine baseline in 62% of patients in the sample as a whole, 60% of the lamotrigine-naïve subgroup, and 63% of the lamotrigine-experienced subgroup. In the sample as a whole, 13% of patients were seizure free during the Treatment Phase. Investigators considered clinical status at the last clinic visit to be improved (mildly, moderately, or markedly) relative to prelamotrigine clinical status in 76% of patients (150/197) and to be unchanged in 19% (37/197). In this study—the first large prospective investigation of the long-term tolerability and efficacy of an antiepileptic drug in a patient population 2 years and younger—lamotrigine administered for up to approximately 72 weeks was well tolerated and associated with good seizure control.

Keywords

lamotrigine epilepsy partial seizures clinical trial

Get full access to this article

View all access options for this article.

References

Hauser WA , Annegers JF , Kurland LT Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984 . Epilepsia. 1993;34:453-468.

Culy CR , Goa KL Lamotrigine: a review of its use in childhood epilepsy. Paediatr Drugs. 2000;2:299-330.

Piña-Garza JE , Levisohn P. , Gucuyener K. , Mikati MA , et al. Adjunctive lamotrigine for partial seizures in patients 1-24 months old [published online ahead of print December 12, 2007]. Neurology . 2008;70(22, pt 2):2099-2108.

Duchowny M. , Pellock JM , Graf WD , Billard C. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology. 1999;53:1724-1731.

Frank LM , Enlow T. , Holmes GL , et al. Lamictal monotherapy for typical absence seizures in children . Epilepsia. 1999;40:973-979.

Motte J. , Trevathan E. , Arvidsson JFV , et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med. 1997;337:1807-1812.

Besag FM , Wallace SJ , Dulac O. , et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr. 1995;127:991-997.

Schlumberger E. , Chavez F. , Palacios L. , et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia. 1994;35: 359-367.

Uvebrant P. , Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics. 1994;25:284-289.

10.

Battino D. , Buti D. , Croci D. , et al. Lamotrigine in resistant childhood epilepsy. Neuropediatrics. 1993;24:332-336.

11.

Herranz JL , Argeaga R. , Armijo JA Three-year efficacy and tolerability of add-on lamotrigine in treatment-resistant epileptic children. Clin Drug Invest. 1996 ;11:214-223.

12.

Farrell K. , Connolly MB , Munn R. , et al. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol. 1997;16:201-205.

13.

Buoni S. , Grosso S. , Fois A. Lamotrigine treatment in childhood drug-resistant epilepsy. J Child Neurol. 1998;13:163-167.

14.

Eriksson AS , Nergardh A. , Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia. 1998;39: 495-501.

15.

Timmings PL , Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol. 1992 ; 32:305-307.

16.

Mikati MA , Fayad M. , Koleilat M. , et al. Efficacy, tolerability and kinetics of lamotrigine in infants . J Pediatrics. 2002;141: 31-35.

17.

Veggiotti P. , Cieuta C. , Rex E. , Dulac O. Lamotrigine in infantile spasms. Lancet. 1994;344:1375-1376.

18.

Uldall P. , Hansen FJ , Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics. 1993;24:339-340.

19.

Stenbom Y. , Tonnby B. , Hagberg B. Lamotrigine in Rett syndrome: treatment experience from a pilot study . Eur Child Adolesc Psychiatr. 1998;7:49-52.

20.

Barron RG , Hunt SL , Hoban TF , Price ML Lamotrigine monotherapy in children. Pediatr Neurol . 2000;23:160-163.

21.

Duchowny M. , Gilman J. , Messenheimer J. , et al. Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J Child Neurol. 2002;17:278-285.

22.

Besag FM , Dulac O. , Alving J. , Mullens EL Long-term safety and efficacy of lamotrigine in paediatric patients with epilepsy . Seizure. 1997;6:51-56.

23.

Fridericia LS Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica . 1920;57:469-486.

24.

Hay AD , Heron J. , Ness A. ; the ALSPAC study team. The prevalence of symptoms and consultations in pre-school children in the Avon longitudinal study of parents and children (ALSPAC): a prospective cohort study. Fam Pract. 2005 ;22:367-374.

25.

Steinhoff BJ , Stodieck SR , Tiecks FP , et al. Cardiac side effects and ECG changes with lamotrigine? A clinical study. Schweiz Arch Neurol Psychiatr . 1994;145:8-12.

26.

Berg AT , Shinnar S. , Testa FM , et al. Mortality in childhood-onset epilepsy. Arch Pediatr Adolesc Med. 2004;158:1147-1152.

27.

Brorson LO , Wranne L. Long-term prognosis in childhood epilepsy: survival and seizure prognosis . Epilepsia. 1987;28: 324-330.

28.

Camfield CS , Camfield PR , Veugelers PJ Death in children with epilepsy: a population-based study. Lancet. 2002;359:1891-1895.

29.

Sillanpää M. , Jalava M. , Kaleva O. , Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med. 1998; 338:1715-1722.

30.

Messenheimer J. Efficacy and safety of lamotrigine in pediatric patients. J Child Neurol. 2002;17(suppl 2):2S34-2S42.

31.

Depot M. , Powell JR , Messenheimer JA Jr , et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther. 1990;48:346-355.